Brian Henick, MD, discussed plans to investigate agents targeting ULBP2/5/6, antibody-drug conjugates, and other novel therapies in lung cancer research.
Brian Henick, MD
Advertisement
Articles by Brian Henick, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma
2
Cisplatin-Free Pembrolizumab Regimen Misses Primary End Point in SMART-KEY
3
Risvutatug Rezetecan Improves PFS in Relapsed/Refractory Osteosarcoma
4
Real-World Data on Cemiplimab Monotherapy Align With Prior NSCLC Studies
5